Perspective Therapeutics
Lead-212 alpha-therapy company whose SSTR2 agent [212Pb]VMT-α-NET reported a 43% response rate in neuroendocrine tumours and is heading for phase 3.
Phase 1/2a of [212Pb]VMT-α-NET (NCT05636618): 43% ORR in cohort 2 with 72% progression-free/alive at the 2026 update; 76 NET patients treated by July 2026; first meningioma patient dosed June 2026; EU orphan designation July 2026. Phase 3 planned at a cumulative 20 mCi dose. Also developing PSMA and melanocortin-1 receptor 212Pb agents.
Pages like this
not linked directly; found by shared links- TechnologyAuger-electron therapy
Shares Alpha vs beta emitters, Somatostatin receptor 2, PSMA, Targeted alpha therapy.
- CompanyOrano Med
Shares Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211, Somatostatin receptor 2, Targeted alpha therapy, Neuroendocrine tumours.
- TermPRRT (peptide receptor radionuclide therapy)
Shares Alpha vs beta emitters, Somatostatin receptor 2, Targeted alpha therapy, Neuroendocrine tumours.
- TechnologyRadioligand plus DNA-repair inhibitor combinations
Shares Somatostatin receptor 2, PSMA, Targeted alpha therapy, Neuroendocrine tumours.
- CompanyRadioMedix
Shares Somatostatin receptor 2, Targeted alpha therapy, Neuroendocrine tumours.
- PairingBeta PRRT → alpha PRRT
Shares Alpha vs beta emitters, Targeted alpha therapy, Neuroendocrine tumours.
- CompanyAktis Oncology
Shares Alpha-emitter nanogenerators and daughter trapping, Targeted alpha therapy.
- IdeaRegional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit